GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Peramivir (Rapivab, adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Rapivab

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Peramivir (Rapivab, adults) - selected U.S. labeling

Product / population
Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.
Renal measure
Cockcroft-Gault CrCl mL/min; explicitly specified in label Table 1.
Labeled basic dosing
Creatinine clearance (mL/min)Single IV treatment dose
50 or higher600 mg
30-49200 mg
10-29100 mg

Administer over 15-30 minutes.

Renal information and dialysis

Use Cockcroft-Gault CrCl for the adult table. In chronic hemodialysis, give the renal-adjusted dose after dialysis. The label table does not supply a separate below-10 non-dialysis dose.

Selected warnings and limits

This single-dose label indication should not be conflated with institutional daily treatment for severe illness. Review serious skin/hypersensitivity and neuropsychiatric warnings.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Peramivir (Rapivab, adults) - selected U.S. labeling

Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Renal method: Cockcroft-Gault CrCl mL/min; explicitly specified in label Table 1.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF peramivir - repeated-dose and dialysis schedules

Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Renal method: CrCl mL/min; IHD and continuous hemodialysis
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Peramivir (Rapivab, adults) - selected U.S. labeling

Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Method: Cockcroft-Gault CrCl mL/min; explicitly specified in label Table 1.

Renal information and dialysisRead this complete source summary
Professional source

UCSF peramivir - repeated-dose and dialysis schedules

Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Method: CrCl mL/min; IHD and continuous hemodialysis

Source-specific renal protocolRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePeramivir (Rapivab, adults) - selected U.S. labelingUCSF peramivir - repeated-dose and dialysis schedules
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d

Product and population scope

Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

RDM31-peramivir-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Peramivir (Rapivab, adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Renal method: Cockcroft-Gault CrCl mL/min; explicitly specified in label Table 1.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Creatinine clearance (mL/min)Single IV treatment dose
50 or higher600 mg
30-49200 mg
10-29100 mg

Administer over 15-30 minutes.

RDM31-peramivir-label-dose · Source locator: 2.1; 2.2 Table 1

Renal information and dialysis

Use Cockcroft-Gault CrCl for the adult table. In chronic hemodialysis, give the renal-adjusted dose after dialysis. The label table does not supply a separate below-10 non-dialysis dose.

RDM31-peramivir-label-renal · Source locator: 2.2

Selected warnings and limits

This single-dose label indication should not be conflated with institutional daily treatment for severe illness. Review serious skin/hypersensitivity and neuropsychiatric warnings.

RDM31-peramivir-label-limits · Source locator: 1; 5.1, 5.2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d
Retrieved
2026-09-05
DailyMed Set ID
fe04f6cd-e71c-4bd4-abac-97720bba2a0d
Renal-function method
Cockcroft-Gault CrCl mL/min; explicitly specified in label Table 1.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
6795ab5f40c9da759ee954aab7676e7aeb3b376fb01440e95289e16be0077d1c
Separate professional-source layer

University and professional protocols

Professional

UCSF peramivir - repeated-dose and dialysis schedules

Open original reference

Open / share this exact local source

University of California San Francisco (UCSF) · Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Renal method: CrCl mL/min; IHD and continuous hemodialysis
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

Printed CrCl band (mL/min)UCSF IV schedule
>50600 mg every 24 hours
30-50200 mg every 24 hours
10-30100 mg every 24 hours
<10100 mg once, then 15 mg every 24 hours

IHD: 100 mg on day 1, then 100 mg two hours after each session. Continuous dialysis: consult ID pharmacy.

RDM31-peramivir-prof-1 · Source locator: Adult and intermittent/continuous hemodialysis tables

Source-specific limits

This is repeated institutional dosing, not the U.S. single-dose uncomplicated-influenza regimen. The printed ranges overlap at 30 and differ at 50 from the label. Confirm an exact-boundary plan with ID pharmacy; do not silently reassign it.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/peramivir
Retrieved
2026-09-05
Renal-function method
CrCl mL/min; IHD and continuous hemodialysis
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
2b62ae9afc29bbc45ef0b1644d649ffbb0fe315ff4a61e9fa5213a69c075b871

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
8989392db0ce2e7a5f76e8c0a59f3359f9c901e01f827f73740d0e4b91e9ee8d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report